Jefferies stays Buy on Protagonist Therapeutics (PTGX) amid JNJ's bullish tone on Icotyde
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $121.00 price target on Protagonist Therapeutics (NASDAQ: PTGX)The analyst commented, "JNJ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
